Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.
Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.
Moderna director Nader Francois increased his direct equity stake through RSU vesting, not open-market buying. On April 30, 2026, 12,174 restricted stock units converted into the same number of Moderna common shares on a one-for-one basis at an exercise price of $0.00 per share.
These RSUs vested in full on that date, reflecting compensation rather than a market trade. Following the conversion, Francois directly owns 32,781 shares of Moderna common stock.
Moderna director Elizabeth E. Tallett exercised restricted stock units into common shares. On April 30, 2026, 4,058 restricted stock units converted into 4,058 shares of Moderna common stock at an exercise price of $0.00 per share. Following this transaction, she directly holds 4,761 common shares. The restricted stock unit award vested in full on April 30, 2026, and the filing shows no remaining derivative position tied to this award.
Moderna reported a sharply wider net loss for Q1 2026 as a major legal settlement overshadowed strong vaccine revenue growth. Total revenue rose to $389 million from $108 million, driven by higher COVID vaccine sales, especially in Europe, and increased stand-ready manufacturing revenue.
Net loss deepened to $1.343 billion, or $(3.40) per share, mainly because cost of sales jumped to $955 million, including about $878 million of royalty and settlement-related expenses tied to resolving global litigation with Arbutus and Genevant. R&D and SG&A both declined year over year as the company tightened spending.
Moderna ended the quarter with $7.456 billion in cash, cash equivalents and investments and a long-term term loan of $600 million. It also signed a $50 million propionic acidemia collaboration with Recordati, continued to receive influenza program funding from Blackstone, and secured European Commission approval for its mCOMBRIAX flu–COVID combination vaccine.
Moderna, Inc. reported first quarter 2026 revenue of $389 million, up from $108 million a year earlier, with $311 million from international markets as COVID vaccine sales rose under long-term government partnerships.
The company posted a GAAP net loss of $1.343 billion, or $(3.40) per share, largely due to a $0.9 billion non-recurring litigation settlement charge recorded in cost of sales. Research and development expenses fell 24% to $649 million and selling, general and administrative expenses decreased 18% to $173 million, reflecting wind-down of large respiratory programs and cost discipline. Cash, cash equivalents and investments totaled $7.5 billion as of March 31, 2026, and Moderna is targeting up to 10% revenue growth for 2026 while projecting year-end cash and investments of $4.5 to $5.0 billion.
Moderna Inc ownership filing reports that Vanguard Capital Management beneficially owned 25,933,824 shares of Moderna common stock, representing 6.53% of the class. The filing lists sole voting power on 3,061,366 shares and sole dispositive power over 25,933,824 shares, and states these holdings include securities held for Vanguard funds and managed accounts. The filing is signed by Ashley Grim on 04/30/2026.
Moderna, Inc. Chief Financial Officer James M. Mock reported routine equity compensation activity. On April 2, 2026, 1,453 restricted stock units converted into an equal number of common shares. These units vest over time, with 25% having vested on October 5, 2023 and the remainder in twelve equal quarterly installments.
To cover tax withholding obligations tied to this vesting, 703 common shares were withheld at $50.03 per share, rather than sold in the open market. As a result, Mock’s direct holdings increased on a net basis, leaving him with 57,748 common shares and 2,906 restricted stock units directly owned after the transactions.
The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting its beneficial ownership of Moderna Inc common stock as 0 shares (0%). The filing explains an internal realignment effective January 12, 2026 that disaggregated certain Vanguard subsidiaries, and it was signed on 03/27/2026.
Moderna is asking shareholders to vote at its virtual 2026 annual meeting on five items, including electing two Class II directors, approving executive pay on an advisory basis, setting say‑on‑pay frequency to one year, and ratifying Ernst & Young as auditor for 2026.
The proxy highlights 2025 results: $1.9 billion in total revenue, about $2.2 billion in annual cost savings (a 30% reduction from 2024), and $8.1 billion in cash, cash equivalents and investments as of December 31, 2025. The company reports three regulatory approvals in infectious disease vaccines and eight Phase 2/3 oncology trials for intismeran autogene with Merck.
mNEXSPIKE became a key U.S. product, representing roughly 24% of all U.S. retail COVID vaccinations in 2025 and nearly one‑third among adults 65+. The Board approved a $1.5 billion five‑year term loan facility to add non‑dilutive capital and oversaw cost discipline, digital investments and expansion of global manufacturing sites.
The nine‑member, staggered Board includes eight independent directors, three women and multiple members with scientific and healthcare backgrounds. Executive pay is positioned as strongly performance‑linked, with 2025 corporate bonuses funded at 170% of target and at‑risk compensation at 91% of target pay for the CEO and 89% for other named executives.